Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on October 18, 2025. The filing discloses material clinical trial results and regulatory updates presented at the ESMO Congress 2025. The Company is a biopharmaceutical firm focused on developing gedatolisib, a PAM pathway inhibitor, for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer (ABC).
Key Financial Metrics
This filing is a regulatory disclosure of clinical data and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Clinical Results
The filing details significant positive topline results from the Phase 3 VIKTORIA-1 trial in the PIK3CA wild-type cohort:
- Gedatolisib Triplet (gedatolisib + palbociclib + fulvestrant): Median Progression-Free Survival (PFS) was 9.3 months versus 2.0 months for fulvestrant alone (Hazard Ratio [HR] 0.24). The Objective Response Rate (ORR) was 31.5% versus 1%, with a median Duration of Response (DOR) of 17.5 months.
- Gedatolisib Doublet (gedatolisib + fulvestrant): Median PFS was 7.4 months versus 2.0 months for fulvestrant alone (HR 0.33). The ORR was 28.3% with a median DOR of 12.0 months.
- Subgroup Analysis: In the U.S. and Canada, median PFS for the triplet was 19.3 months (HR 0.13) and for the doublet was 14.9 months (HR 0.35).
- Phase 1b Data: Additional data showed median PFS of 14.6 months (ORR 48%) for PIK3CA mutant-type patients and 9.0 months (ORR 41%) for PIK3CA wild-type patients.
Guidance, Outlook, and Risks
Regulatory Outlook: Celcuity initiated a rolling New Drug Application (NDA) submission with the FDA under the Real-Time Oncology Review program based on the PIK3CA wild-type cohort data. Completion of the NDA is targeted for the fourth quarter of 2025.
Future Milestones: The PIK3CA mutant cohort of the VIKTORIA-1 trial is 100% enrolled, with topline data expected in late Q1 2026 or Q2 2026.
Safety Profile: The treatments were generally well tolerated. The most common Grade 3 treatment-related adverse events (TRAEs) for the triplet included neutropenia (52.3%), stomatitis (19.2%), and rash (4.6%). Discontinuation due to TRAEs occurred in 2.3% of triplet patients and 3.1% of doublet patients.
Risks: The filing includes standard forward-looking statement disclaimers regarding the preliminary nature of the data, potential delays in NDA approval, and the uncertainty of regulatory outcomes.
Investor Verification Checklist
- Verify the final NDA submission timeline and FDA acceptance status in Q4 2025.
- Monitor the upcoming topline data release for the PIK3CA mutant cohort (expected late Q1/Q2 2026).
- Review the full safety data and long-term survival analysis once mature data becomes available.
- Assess the commercialization strategy and potential partnership opportunities following potential FDA approval.